Omniscan and Skin hypopigmentation - a phase IV clinical study of FDA data

Summary:

Skin hypopigmentation is reported as a side effect among people who take Omniscan (gadodiamide), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Optimark, and have Nuclear magnetic resonance imaging brain.

The phase IV clinical study analyzes which people have Skin hypopigmentation when taking Omniscan. It is created by eHealthMe based on reports of 6,166 people who have side effects when taking Omniscan from the FDA, and is updated regularly.

What is Omniscan?

Omniscan has active ingredients of gadodiamide. eHealthMe is studying from 6,169 Omniscan users. Check the latest studies of Omniscan.

What is Skin hypopigmentation?

Skin hypopigmentation (loss of skin colour) is found to be associated with 158 drugs and 286 conditions by eHealthMe. Check the latest studies of Skin hypopigmentation.

On Jul, 10, 2026

6,166 people reported to have side effects when taking Omniscan.
Among them, 24 people (0.39%) have Skin hypopigmentation.

Could Omniscan cause Skin hypopigmentation?

Among these 24 people:

How long have people been on Omniscan when they have Skin hypopigmentation? *

What is the gender of people who have Skin hypopigmentation when taking Omniscan? *

female: 78.26 %
male: 21.74 %

What is the age of people who have Skin hypopigmentation when taking Omniscan? *

What are other drugs people take besides Omniscan? *

What are other side effects people have besides Skin hypopigmentation? *

Nephrogenic Systemic Fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease): 24 people, 100.00%
Rashes (redness): 20 people, 83.33%
Pain: 20 people, 83.33%
Pain In Extremity: 15 people, 62.50%
Skin Hypertrophy (skin cells enlarges): 15 people, 62.50%
Scar: 15 people, 62.50%
Skin Discoloration: 14 people, 58.33%
Skin Tightness: 13 people, 54.17%
Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves): 12 people, 50.00%
Oedema Peripheral (superficial swelling): 12 people, 50.00%

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 8 people, 33.33%
Pain: 4 people, 16.67%
Nuclear Magnetic Resonance Imaging Abdominal: 4 people, 16.67%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 4.17%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 4.17%
Kidney Transplant Rejection: 1 person, 4.17%
High Blood Pressure: 1 person, 4.17%
High Blood Cholesterol: 1 person, 4.17%
Fluid Retention (an abnormal accumulation of fluid in the blood): 1 person, 4.17%
Computerised Tomogram Abdomen: 1 person, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Omniscan and have Skin hypopigmentation?

- Check whether Skin hypopigmentation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Omniscan:

Omniscan (6,169 reports)

Browse all side effects of Omniscan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin hypopigmentation:

Skin hypopigmentation (158 drugs)

Browse all the conditions that are associated with Skin hypopigmentation:

Skin hypopigmentation (286 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gadodiamide (the active ingredients of Omniscan) and Omniscan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.